Keywords: GlaxoSmithKline, Theravance, Umeclidinium, Vilanterol, LAMA?LABA, COPD, Ph III, Global filings

GSK completes LAMA/LABA Ph III program; readies for global filings

Article | 28 August 2012

Print This

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) say they have completed the Phase III program ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in